Menkes Syndrome Market By Drug Class (Penicillamine, Droxidopa, Others), By Route of Administration (Oral, Parental), By Application (Hospitals, Specialty Clinics, Home Care Settings) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032

Introduction

Copper is an essential mineral required by the human body that is critical for several functions such as metabolism, brain functioning, blood cell formation, etc. The human body uses copper in very small quantities. Wound healing and converting iron to a usable form in the body are some other functions or uses of copper. Copper is available in several foods and dietary supplements.

Menkes syndrome, also known as Menkes disease, is caused by the mutation of the ATP7A gene, which affects how the body maintains copper levels and transports copper. It is characterized by kinky hair, the failure to gain weight, and failure to grow at the expected rate. Other signs and symptoms include hypotonia, seizures, intellectual disability, and sagging facial features.

Children develop symptoms during infancy and often do not survive past 3 years. Early treatment with copper may improve the prognosis in some individuals. Sometimes in rare cases, symptoms arise later on in childhood. This disease mostly occurs in male infants, with a probability of 1 in 35,000 male births. It primarily causes low levels of copper in the blood plasma, liver, and brain.

Request Covid - 19 Impact

The global Menkes syndrome market is segmented based on – drug class, route of administration, end-user, and region.

Listed below is this market’s segmentation:

By Drug Class

• Penicillamine
• Droxidopa
• Others

Route of Administration

• Oral
• Parental

End-User

• Hospitals
• Specialty Clinics
• Home Care Settings

By Region

• North America
o The US
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Russia
o Rest of Europe
• Asia-Pacific
o China
o Japan
o India
o Korea
o Rest of the Asia-Pacific
• South America
o Brazil
o Argentina
o Rest of South America
• the Middle East and Africa
o GCC
o Israel
o South Africa
o Rest of the MEA

Market Dynamics–

Increasing awareness levels concerning Menkes syndrome, coupled with ongoing investments in the healthcare industry, are factors expected to boost the revenue growth prospects of this target market. Unfortunately, lower awareness of this disease in developing nations, the higher cost of treatment, and the onset of the ongoing COVID-19 pandemic are major factors expected to negatively impact this market’s economic growth. Additionally, key industry players invest in R&D activities to develop new drugs and treatment methods for Menkes syndrome.

This factor is expected to create opportunities for industry players, thereby further contributing to the revenue growth of this market over the forecast period. Moreover, various governments and NGOs are focusing on increasing awareness levels concerning genetic disorders by organizing camps and free check-up centers. These factors are also expected to boost this target market’s revenue growth in the years to come.

Competitive Landscape

Major players in this market are -

• Fortress Biotech
• Teva Pharmaceutical Industries Ltd.
• Amerigen Pharmaceuticals Limited
• Mylan N.V.
• Bausch Health
• H. Lundbeck A/S, among others.

Key Developments:

In 2021, Cadila Healthcare announced that its US subsidiary acquired an experimental drug from Cyprium to treat Menkes disease.

In 2020, Cyprium Therapeutics Inc., launched CUTX-101, a subcutaneous injectable formulation of copper histidinate, which helps to restore copper hemostasis and maintain serum copper levels at an appropriate range.

For the Menkes Syndrome Market research study, the following years have been considered to estimate the market size: